Related Experiment Video
Updated: Feb 6, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer
Chunxiao Sun1,2, Fan Yang1,2, Yanhong Zhang1,2
1Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background/Aims:
Resistance to trastuzumab remains a common challenge to HER-2 positive breast cancer. Up until now, the underlying mechanism of trastuzumab resistance is still unclear. tRNA-derived small non-coding RNAs, a new class of small non-coding RNA (sncRNAs), have been observed to play an important role in cancer progression. However, the relationship between tRNA-derived fragments and trastuzumab resistance is still unknown.
Methods:
We detected the levels of tRNA-derived fragments expression in normal breast epithelial cell lines, trastuzumab-sensitive and -resistant breast cancer cell lines using high-throughput sequencing. qRT-PCR was conducted to validate the differentially expressed fragments in serums from trastuzumab-sensitive and -resistant patients. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the power of specific tRNA-derived fragments. Progression-free survival (PFS) was analyzed using Cox-regression.
Results:
Our sequence results showed that tRNA-derived fragments were differentially expressed in the HBL-100, SKBR3, and JIMT-1 cell lines. tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN were found significantly upregulated in trastuzumab-resistant patients compared to sensitive individuals, and the ROC analysis showed that tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN were correlated with trastuzumab resistance. In a multivariate analysis, higher levels of tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN expression were associated with significantly shorter PFS in patients with metastatic HER-2 positive breast cancer.
Conclusion:
Our results suggest that tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN play important roles in trastuzumab resistance. Patients with high levels of tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN expression benefitted less from trastuzumab-based therapy than those that express lower-levels of these molecules. tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN may be potential biomarkers and intervention targets in the clinical treatment of trastuzumab-resistant breast cancer.
Insights
Two tRNA-derived fragments, tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN, are linked to trastuzumab resistance in HER-2 positive breast cancer. Higher levels of these fragments indicate poorer response to trastuzumab therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Trastuzumab resistance is a significant obstacle in treating HER-2 positive breast cancer.
- The mechanisms underlying trastuzumab resistance are not fully understood.
- tRNA-derived small non-coding RNAs (sncRNAs) are emerging as key players in cancer progression.
Purpose of the Study:
- To investigate the role of tRNA-derived fragments (tRFs) in trastuzumab resistance in HER-2 positive breast cancer.
- To identify potential biomarkers for predicting response to trastuzumab therapy.
Main Methods:
- High-throughput sequencing to detect tRF expression in breast cancer cell lines.
- Quantitative reverse transcription PCR (qRT-PCR) to validate tRF levels in patient serum.
- Receiver operating characteristic (ROC) curve analysis to assess diagnostic power.
- Cox-regression analysis for progression-free survival (PFS).
Main Results:
- tRFs were differentially expressed in trastuzumab-sensitive and -resistant cell lines.
- tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN were significantly upregulated in trastuzumab-resistant patients.
- ROC analysis confirmed the association of these tRFs with trastuzumab resistance.
- Elevated levels of tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN correlated with shorter PFS in metastatic HER-2 positive breast cancer patients.
Conclusions:
- tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN are implicated in trastuzumab resistance.
- Patients with high expression of these tRFs may benefit less from trastuzumab treatment.
- These tRFs show potential as biomarkers and therapeutic targets for trastuzumab-resistant breast cancer.
Related Concept Videos
tRNA Activation
tRNA Activation
Treatment Resistant Cancers
Habitat Fragmentation
Predicting Molecular Geometry
Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.

